Dr. Medvedova is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
# Ohsu
Portland, OR 97239Phone+1 503-494-7999
Education & Training
UMass Chan Medical SchoolFellowship, Hematology and Medical Oncology, 2007 - 2010- UMass Chan Medical SchoolResidency, Internal Medicine, 2004 - 2007
Comenius UniversityClass of 2002
Certifications & Licensure
OR State Medical License 2013 - 2025
MA State Medical License 2009 - 2014
CT State Medical License 2010 - 2012- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- 28 citationsStem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER ...Saurabh Chhabra, Natalie Callander, Nicole L Watts, Luciano J Costa, Bicky Thapa
Transplantation and Cellular Therapy. 2023-03-01 - 5 citationsDaratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, Kelly N Godby, Jacob Laubach
Blood Cancer Journal. 2024-04-22 - 22 citationsMinimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.Luciano J Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R Dholaria, Timothy M Schmidt
The Lancet. Haematology. 2023-11-01
Abstracts/Posters
- Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...Eva Medvedova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma...Eva Medvedova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
